• Hematological Malignancy Program

    Every year, researchers identify novel molecular aberrations associated with hematologic malignancies. Likewise, the advent of high-throughput sequencing projects will significantly expand the cadre of genes implicated in leukemogenesis. Understanding how these aberrant genes contribute to the development of various hematologic neoplasms is the major goal of the Hematologic Malignancies Program (HMP).  

    We are currently focusing on acute leukemia, myelodysplasia and myeloproliferative syndromes using a variety of approaches to model and dissect these diseases. One major approach is to use murine genetic models, including knockin, knockout and transgenic mice, to model the human diseases associated with loss or overexpression of individual genes. A complement to this approach is to use retroviral or lentiviral delivery to overexpress or knock down particular genes in primary human or murine blood stem and progenitor cells. In addition, our labs use patient samples as the ultimate validation of the findings obtained with these model systems.  

    HMP members have access to a world-class mouse core as part of the NIDDK-designated Center of Excellence in Hematology P30 core grant. This includes state-of-the-art xenograft models for expanding patient samples in vivo. Through these efforts, HMP members are testing new experimental therapies for hematologic malignancies. 

    The HMP facilitates interdisciplinary collaborations among researchers at Cincinnati Children’s and promotes a bench-to-bedside mentality that encourages clinicians and basic researchers to pool efforts and resources to achieve shared goals.  

    HMP members come from six divisions within Cincinnati Children’s and represent expertise in hematopoietic stem cell transplant, pathology, epigenetic modifications, human ES cell manipulation and the molecular biology and biochemistry of hematologic malignancy.

    A major goal of the program is to study mechanisms regulating normal and malignant hematopoietic stem and progenitor cells and to develop therapies based on manipulating malignant stem cells using the knowledge gained through experimentation.

    Cancer Pathology Program


    Lee Grimes, PhD program leader
    Mohammad Azam, PhD
    Gang Huang, PhD

    James Mulloy, PhD co-program leader
    Lee Grimes, PhD co-program leader
    Mohammad Azam, PhD
    Gang Huang, PhD
    Ashish Kumar, MD, PhD
    Benjamin Mizukawa, MD
    Daniel T. Starcynowski, PhD

    Adjunct Faculty
    David Plas, PhD - University of Cincinnati
    Jim Driscoll, MD/PhD – University of Cincinnati
    Rhett Kovall, PhD - University of Cincinnati
    Eddie Merino, PhD - University of Cincinnati
    Jianjun Chen, PhD - University of Cincinnati